<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669641</url>
  </required_header>
  <id_info>
    <org_study_id>SteatoSPC</org_study_id>
    <secondary_id>1334/17.12.2015</secondary_id>
    <nct_id>NCT02669641</nct_id>
  </id_info>
  <brief_title>Complex Imaging Assessment of Steatosis</brief_title>
  <acronym>SteatoSPC</acronym>
  <official_title>Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Pharmacy Craiova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fiterman Pharma SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Medicine and Pharmacy Craiova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is the assessment of MRI (Magnetic Resonance Imaging) Spectroscopy in
      patients diagnosed with hepatic steatosis in treatment with combination Silimarin,
      Phyllanthus Niruri and Choline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study will be included patients with alcoholic and non-alcoholic steatohepatitis
      evaluated in Research Center of Gastroenterology and Hepatology and Gastroenterology Clinic
      of University of Medicine and Pharmacy of Craiova. All the patients will undergo MRI and MRI
      Spectroscopy (3 Tesla) using PHILIPS INGENIA 3T System for exact steatosis quantification.
      The eligible patients will be treated with combination Silimarin, Phyllanthus Niruri and
      Choline (Stoptoxin Forte) for 6 months (in conformity Product Characteristics). After the
      treatment a new IRM Spectroscopy examination will be performed. All the acquired data will be
      analyzed and published.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat-fraction</measure>
    <time_frame>6 months after specific treatment</time_frame>
    <description>MRI Spectroscopy is the most direct non-invasive MR-based method to separate the liver signal into its water and fat components and calculate a signal fat-fraction.
To calculate the fat fraction record the area of lipid peak, the area of the water peak and the fat fraction is lipid area/(lipid area+ water area)×100.
The signal fat-fraction with MRI Spectroscopy has a dynamic range of 0-100%. Steatosis grades are categorized into broad brackets of severity: grade 0 (normal) = up to 5% of cells affected, grade 1 (mild) = 5-33% of cells affected, grade 2 (moderate) = 34-66% of cells affected, and grade 3 (severe) ≥67% of cells affected.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Steatosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diagnosed steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Combination Silimarin, Phyllanthus niruri and Choline</intervention_name>
    <description>Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.</description>
    <arm_group_label>Steatosis</arm_group_label>
    <other_name>Stoptoxin Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  steatosis described on abdominal ultrasound

        Exclusion Criteria:

          -  chronic viral hepatitis

          -  liver cancer

          -  abusive alcohol consumption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioana Andreea Gheonea, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>University of Medicine and Pharmacy Craiova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ioana Andreea Gheonea, Lecturer</last_name>
    <phone>+40751268732</phone>
    <email>iagheonea@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Ionut Gheonea, Assoc. Prof.</last_name>
    <phone>+40751268731</phone>
    <email>digheonea@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Center in Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Romania</name>
      <address>
        <city>Craiova</city>
        <state>Please Select</state>
        <zip>200349</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioana Andreea Gheonea, Lecturer</last_name>
      <phone>+40751268732</phone>
      <email>iagheonea@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dan Ionut Gheonea, Assoc. Prof.</last_name>
      <phone>+40751268731</phone>
      <email>digheonea@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>http://umfcv.ro/steatospc</url>
    <description>The official website</description>
  </link>
  <reference>
    <citation>Kirpich IA, Miller ME, Cave MC, Joshi-Barve S, McClain CJ. Alcoholic Liver Disease: Update on the Role of Dietary Fat. Biomolecules. 2016 Jan 6;6(1):1. doi: 10.3390/biom6010001. Review.</citation>
    <PMID>26751488</PMID>
  </reference>
  <reference>
    <citation>Gheonea DI, Săftoiu A, Ciurea T, Gorunescu F, Iordache S, Popescu GL, Belciug S, Gorunescu M, Săndulescu L. Real-time sono-elastography in the diagnosis of diffuse liver diseases. World J Gastroenterol. 2010 Apr 14;16(14):1720-6.</citation>
    <PMID>20380003</PMID>
  </reference>
  <reference>
    <citation>Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, Motosugi U, Sharma SD, Munoz del Rio A, Fernandez L, Reeder SB. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Hepatology. 2015 Nov;62(5):1444-55. doi: 10.1002/hep.28012. Epub 2015 Sep 28.</citation>
    <PMID>26224591</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steatosis, Fatty liver, Steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

